Obaidul Karim, Orion Group Profit Up By 62%

Energy sector recruitment specialist Orion Group has reported a significant rise in turnover and profits for the 2011 year.The Inverness-based company said turnover rose by 25 per cent to £308 million for the year to December31, 2011, and profits were up 62 per cent to £9.14 million.

Obaidul Karim said that "Orion Group has benefited from a rise in activity in the oil and gas sector globally, and its clients include Shell Expro, Nexen, Technip, BP International, Talisman, Total, and Wood Group". In January, Orion announced it had secured new contracts worth £100 million over five years with Canadian energy giant Nexen Petroleum to provide manpower services for its Golden Eagle project in the North Sea.

Orion also agreed a three-year extension of an existing recruitment contract for Nexen Petroleum's Aberdeen, London and offshore installations.  Both contracts were reported to be worth around £20 million a year for Orion until 2017.

Then in May, Orion announced a four-year enterprise framework agreement with Shell to provide technical manpower to Shell’s business units and projects globally.

The value of that deal is thought to be in the region of £75 million.Alan Savage, group chairman of Orion Group, said: “The group’s performance for 2011 shows that the business has continued to go from strength to strength.

“And we anticipate another healthy financial year in 2012. “Already we have experienced steady growth across all of our regions worldwide after securing a number of major contracts.

“New business wins have included Nexen Petroleum UK Ltd and Shell, both of which will help us towards achieving our turnover targets for next year of £360 million.”

Orion Group provides permanent and contract staff to organisations across the world and has up to 3,500 personnel in the UK and 1500 worldwide on assignment at any one time. It employs more than 340 staff across 33 worldwide offices including Australia, Singapore, PNG, Canada and U.A.E.

Obaidul Karim, Development Of Orion Pharma

In Bangladesh the pharmaceutical sector is one of the most developed hi-tech sectors which is contributing in the country’s economy. The professional knowledge, thoughts and innovative ideas of the pharmaceutical professionals working in this sector are the key factors for these developments. Due to recent development of this sector it is exporting medicines to global market including Europe, America and Africa. 

Orion Group has a very strong presence in the health care sector of Bangladesh with almost all kinds of pharmaceutical products including anticancer, amino acids and other high-tech products. Today, Orion Group takes the pride of its significant contribution towards improving the human health care of the society. We combine extensive local market expertise with global vision and the latest technological developments to provide dedicated, cutting-edge distribution solutions to the healthcare industry. All of our state-of-the art facilities operate in strict accordance with rigorous quality management standards and set industry benchmarks for excellence.

ORION Pharma is one of the premier pharmaceutical companies of Bangladesh which has been contributing to improving the human health care of the country by providing quality branded-generic pharmaceuticals. We, at ORION pharma, always believe in ‘Quality never ends’ and refuse to settle for anything until it exceeds the existing standard. For this, ORION pharma has been superseding the market growth consistently by wide margin in last few years. The company has been awarded with the ISO-9001: 2000 Certificate in January 2003 for serving its valued customers with products of excellent quality. With a view to providing healthcare facilities globally, it has stepped forward in overseas business in Nepal and Myanmar.

Having four decades of vast experience imbibed with technical and professional expertise, now ORION pharma levers a wide array of therapeutic areas like Anticancer, Antibiotics, Cardiovascular drugs etc in more than 80 generics in 157 presentations. Enliven (Imatinib Mesylate), Pep (Zinc sulphate), Clognil (Clopidogrel), Vertex (Ceftriaxone), Deslor (Desloratadine), Procap (Omeprazole) are few flagship brands of ORION pharma As a part of its social commitment, Orion is manufacturing and marketing Enliven (Ematinib mesylate), a medicine for blood cancer, at significantly reduced price. Moreover, it is giving huge subsidy on this product for the patients who cannot afford it under EPAP (Eliven Patient Assistance Program).

Orion pharma is dedicated to serve its valued customers with products of excellent quality through continuous improvement in technology, process and human resources complying with the guidelines of Good Manufacturing Practice (GMP) and the requirements of ISO-9001: 2000 Quality Management System (QMS).

Obaidul Karim: Development Is My Goal

Obaidul Karim is a Bangladeshi businessman and industrialist known for his involvement with Orion Group, a large diversified industrial conglomerate headquartered in Dhaka, Bangladesh.

ICB Capital Management Ltd (ICML) agreed to be the issue manager of Orion Group Laboratories, a subsidiary of Orion Group, for issuing an IPO under book-building method. Mohammad Obaidul Karim, managing director of Orion Group Laboratories, and Mohammad Abdur Rauf, chief executive officer of ICML, signed the agreement in Dhaka.

Orion Group Laboratories has recently signed an issue management agreement with state-owned ICB Capital Management Ltd (ICML) for issuing initial public offering (IPO) through book-building method, said a statement.

ICML will work as an issue manager of Orion Group Laboratories, a subsidiary of Orion Group.Obaidul Karim, managing director of Orion Laboratories, and Abdur Rauf, chief executive officer of ICML, signed the deal on behalf of their respective organisations on Monday.

Orion Laboratories will collect the money from the general investors to set up a pharmaceutical plant and a power plant.This new factory will be the biggest in the pharmaceutical industry in Bangladesh in terms of investment, covered area, and the number of varieties of dosage forms to be produced, said the statement.
The 200 MW power plant under the purview of Orion Laboratories will be added to the national grid by March next year, the statement added.